A Phase 1 interventional study of UCART123v1.2 in Relapsed/Refractory Acute Myeloid Leukemia, sponsored by Cellectis S.A.. Active, not recruiting at 8 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by Cellectis S.A. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.
Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 1,089th largest by enrollment of the 1,908 interventional ones that give a count, is one of 99 that started in 2017, is one of 772 in phase 1, reaches primary completion later than 52 of the 461 other live ones, and was the 1,382nd registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:
Uma Borate · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1,078 · Phase 2 971 · Phase 3 139 · Phase 4 7
First in 1986; this study’s year is marked. 99 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 35 across the 1,908 interventional studies, 98 across the 126 observational. Of the 1,558 that completed or were terminated, 709 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
574 of 2,138 have an industry lead sponsor. The 10 most frequent:
Cellectis S.A. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Cellectis S.A. has 2 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
168 of the studies in Leukemia, Myeloid, Acute with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT05429632Phase 3Priothera SASMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | 2027-05 |
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT03121014University of Illinois at ChicagoStudy of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes | 2026-11 |
Add all 168 to your calendar (.ics) → With an account.
Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of Universal Chimeric Antigen Receptor T-cells targeting CD123 (UCART123v1.2) and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
UCART123v1.2 tested at several dose levels with different lymphodepletion regimens to establish Maximum Tolerated Dose (MTD) and identify Recommended Phase 2 Dose (RP2D) Dose Expansion: UCART123v1.2 administered at the RP2D determined from the dose escalation phase
Biological: UCART123v1.2
Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor Biological/vaccine: CLLS52 A monoclonal antibody that recognizes the CD52 antigen Other Names: Alemtuzumab
Incidence of adverse events (AE)/serious adverse events (SAE)/Dose Limiting Toxicities (DLT) [Safety and Tolerability]
Safety of UCART123v1.2 - Incidence, nature, and severity of AE and SAEs throughout the study
Time frame: 24 Months
Dose escalation and expansion part: Occurrence of DLTs
Time frame: Up to Day 28 post last UCART123v1.2 infusion
Investigators assessed overall response rate according to the European Leukemia Net (ELN) Response Criteria
Time frame: At Day 28, Day 56, Day 84, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21 and Month 24
Duration of Response
Time frame: From the date of the initial response to the date of disease progression or death from any cause, whichever occurs first, assessed up to Month 24
Progression Free Survival
Time frame: From the first day of study treatment to the date of disease progression or death from any cause, whichever occurs first, assessed up to Month 24
Overall Survival
Time frame: From the first day of study treatment to the date of death from any cause, assessed up to Month 24
Pharmacokinetic (PK) Analysis: Standard PK Analysis will be completed to obtain Maximum plasma concentration (Cmax)
Time frame: alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose
Pharmacokinetic Analysis: Standard PK Analysis will be completed to obtain time to reach Cmax (Tmax)
Time frame: alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose
Pharmacokinetic Analysis: Standard PK Analysis will be completed to obtain total area under curve from zero to infinity (AUC-infinity)
Time frame: alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose
Pharmacokinetic Analysis: Standard PK Analysis will be completed to obtain Terminal Rate
Time frame: alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose
Pharmacokinetic Analysis: Standard PK Analysis will be completed to obtain Terminal Half-life
Time frame: alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose
Pharmacokinetic Analysis: Standard PK Analysis will be completed to obtain Clearance
Time frame: alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose
Pharmacokinetic Analysis: Standard PK Analysis will be completed to obtain Volume of Distribution
Time frame: alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose
Pharmacodynamic Analysis: Pharmacodynamics Monitoring of the incidence of anti-cluster of differentiation 52 (anti-CD52; alemtuzumab) antibodies (ADA) in serum Pre-alemtuzumab administration and through Day 84
Time frame: From screening through Day 84
Pharmacodynamic Analysis: Pharmacodynamics Quantitation of T cells in peripheral blood
Time frame: From screening through Day 84
Pharmacodynamic Analysis: Pharmacodynamics Quantitation of B cells in peripheral blood
Time frame: From screening through Day 84
Pharmacodynamic Analysis: Pharmacodynamics Quantitation of natural killer (NK) cells in peripheral blood
Time frame: From screening through Day 84
Pharmacodynamic Analysis: Pharmacodynamics Quantitation of total lymphocytes in peripheral blood
Time frame: From screening through Day 84
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2017 to primary completion in Dec 2024, 90 months.
Of 182 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 90 months is above that.
Counting every sponsor, half of 489 studies reached it within 49 months; a quarter within 31 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cellectis S.A.